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ABSTRACT 17 
 18 
Objective The success of antiretroviral therapy (ART) of HIV-1 is compromised by 19 
development of drug resistance (DR) due to mutations in viral target genes. Monitoring 20 
of these DR mutations will help to avoid continuation of ineffective therapies and 21 
contribute to optimization of ART. In Tanzania, molecular analysis of DR is currently 22 
limited owing to high cost. Therefore, a simple, inexpensive and robust tool for DR 23 
genotyping was developed based on microarray technology and was restricted to 25 DR 24 
mutations most relevant for the locally available ART regimen. 25 
 26 
Methods The reverse transcriptase gene fragment was reverse transcribed and 27 
amplified by Reverse Transcription-Polymerase Chain Reaction (PCR). Primers for 28 
mini-sequencing were designed based on alignments of most prevalent local HIV-1 29 
variants. Tagged primers were extended by fluorochrome-labeled dideoxynuclotide 30 
triphosphate (ddNTPs) to indicate the Single Nucleotide Polymorphism (SNP) allele of 31 
the sample tested, followed by hybridization on treated microarray slides. Images were 32 
analyzed with a laser scanner and genotype calling was performed using in-house 33 
developed software. The microarray was validated with four cloned HIV-1 genome 34 
fragments from Swiss HIV-1 Cohort and 102 HIV-1 sequences amplified from 35 
Tanzanian target population (field samples) and the results were concordant with the 36 
Sanger sequencing SNP profile in 92.7% of 2550 SNP data points compared. Lack of 37 
signals in small number of SNPs was due to either failure in extension reaction or 38 
hybridization owing to excessive mismatches between PCR product and extension 39 
primer.  40 
   41 
Conclusion Our study demonstrates the feasibility of hybridization-based genotyping 42 
of drug resistance mutations of HIV, even though the microarray, which was designed 43 
for population studies, could achieve an assignment of only 92% for the individual SNPs 44 
in the tested samples.  45 
46 
INTRODUCTION 47 
Development of HIV-1 drug resistance has been a major obstacle in the long-term 48 
success of Antiretroviral Therapy (ART) for HIV-1 patients (Shafer et al., 2000). One of 49 
the main factors accounting for the development of drug resistance is the emergence of 50 
mutations in the reverse transcriptase gene, which is the major HIV-1 drug target (Bean, 51 
2005). 52 
 53 
A number of phenotypic and genotypic assays have been used to detect HIV-1 drug 54 
resistance (DR) mutations (Grant and Zolopa, 2009). Phenotypic assays measure 55 
directly the extent to which an antiretroviral drug inhibits HIV-1 replication in-vitro, and 56 
determine an increase in the inhibitory concentration that is required to inhibit in-vitro 57 
replication by 50 percent compared with virus replication in the absence of drug. Results 58 
are reported as fold-change in drug susceptibility of the patient-derived virus sample 59 
compared with a laboratory reference strain of HIV-1 (MacArthur, 2009). Phenotypic 60 
testing reflects the net effect of HIV-1 mutations on susceptibility to each tested drug 61 
and has advantages in patients with complex mutation patterns (Hirsch et al., 2008). 62 
Genotypic HIV resistance assays assess known mutations associated with drug 63 
resistance. These assays involve the detection of genomic HIV-1 mutations in regions 64 
that are targeted by the current ARV drugs, mainly protease, reverse transcriptase, 65 
integrase, and envelope glycoprotein 41. Following amplification of the genes of interest 66 
by reverse transcription-PCR, the amplicons can further be processed by two different 67 
approaches: either direct sequencing or hybridization-based methods. While 68 
sequencing determines the full nucleotide sequence of the selected gene for analysis, 69 
hybridization targets only specific SNPs of interest. Compared to phenotypic assays, 70 
genotypic testing has the advantages of shorter turn-around time and lower cost (Hirsch 71 
et al., 2008). 72 
  73 
While in developed countries both genotypic and phenotypic assays are routinely used 74 
for monitoring HIV-1 patients at initiation of ART and in case of suspected drug 75 
resistance, these assays are currently rarely available in developing countries due to 76 
their prohibitive costs. In view of the rapidly increasing need for molecular monitoring of 77 
the prevalence and spread of DR also in resource-poor settings, an additional molecular 78 
tool for robust and affordable DR genotyping is warranted. While nucleotide sequencing 79 
certainly remains the gold standard for molecular detection of DR-SNPs, surveillance of 80 
population samples and molecular epidemiological research project in developing 81 
countries like Tanzania could greatly benefit from a simple and robust tool to determine 82 
the limited number of DR-SNPs that are most critical for a specific location and available 83 
drugs and drug combinations. We therefore investigated the option to genotype multiple 84 
SNPs using a standard microarray platform.  85 
 86 
A related microarray platform had been developed previously in our laboratory for 87 
detection of SNPs in drug resistance marker genes of malaria parasites (Crameri et al., 88 
2007). For this application the mini-sequencing principle was validated with highly 89 
specific base calling and parallel genotyping of many SNPs at a time (Syvänen, 1999). 90 
We intended to adopt this platform for genotyping local HIV-1 variant in Ifakara, a site in 91 
rural Tanzania. For this proof-of-concept the HIV-1 microarray was restricted to 92 
mutations associated with resistance to the available reverse transcriptase inhibitors 93 
(RTI) in use in the Ifakara HIV-1 cohort, i.e. stavudine, lamivudine, zidovudine, abacavir, 94 
didanosine, nevirapine, and efavirenz. 95 
 96 
Due to the intrinsic high error rate of the HIV-1 polymerase extensive polymorphisms 97 
are generally observed among circulating HIV-1 strains. Therefore we focused the 98 
design of primers on local subtypes and strains occurring in the study area. Our 99 
intention was to provide an affordable option for monitoring HIV-1 drug resistance in 100 
Ifakara, Tanzania, by genotyping via microarray; this would permit a highly multiplexed 101 
SNP analysis in a single run, requiring little hand-on-time and resources as 102 
demonstrated in the malaria chip-project (Crameri et al., 2007).  103 
 104 
MATERIALS AND METHODS 105 
 106 
Patients and plasma samples 107 
Samples used in this study were obtained from HIV-1 patients from the KIULARCO HIV 108 
cohort of Ifakara, Tanzania. KIULARCO was established in 2004 in Kilombero and 109 
Ulanga districts, Morogoro region, Southern Tanzania, for the purpose of implementing 110 
care and treatment of HIV/AIDS patients according to Tanzania National AIDS Control 111 
Care Programme (NACP) and to conduct – alongside with offering these essential 112 
services - applied research on minimal essential care and monitoring for HIV patients in 113 
rural resource-poor, peripheral settings. Patients were enrolled at the Chronic Disease 114 
Center Ifakara (CDCI) affiliated with Ifakara Health Institute and St. Francis Referral 115 
Hospital (SFRH), the main district hospital providing treatment and care for a population 116 
of more than 600,000 and for 30,000 people living with HIV/AIDS (Mossdorf et al., 117 
2011).  118 
Plasmid-cloned HIV-1 genes used for validation of the microarray stemmed from 119 
anonymous clinical HIV-1 samples collected in Switzerland.  120 
 121 
Ethical Considerations 122 
This study was approved by ethics review bodies of Tanzania, the Ifakara Health 123 
Institute (IHI) Institutional Review Board, and the Medical Research Coordination 124 
Committee of the National Institute for Medical Research (NIMR) through the Tanzania 125 
Commission for Science and Technology (COSTECH) and the Ethics Committee of 126 
Canton Basel (EKBB), Switzerland. Patients taking part in this study had given their 127 
informed written consent. 128 
 129 
RNA extraction, Reverse Transcription and PCR  130 
Viral RNA was extracted from plasma with either the QIAamp Viral RNA Mini Kit 131 
(Qiagen, Hilden, Germany) or Macherey-Nagel NucleoSpin RNA Virus Kit (Macherey-132 
Nagel GmbH & Co KG, Neumann-Neander, Germany) using the manufacturers’ 133 
protocols.  134 
 135 
Reverse transcription was performed using specific primer RT2, AffinityScript RT Buffer 136 
(500 mM TrisHCl pH 8.3, 750 mM KCl, 30 mM MgCl2), 2 µL of 100 mM DTT 137 
(Stratagene, North Torrey Pines Road La Jolla, CA), 0.8 µL dNTP mix (25 mM each 138 
dNTP), 1 µL of a RNase Inhibitor, RNase Out (40 U/µL), 1 µL AffinityScript Multiple 139 
Temperature Reverse Transcriptase, 1 µL specific Primer RT2 (5’-140 
GATAAGCTTGGGCCTTATCTATTCCAT-3`), (10 µM), HPLC purified, and 9.5 µL RNA 141 
solution. Reverse transcription was performed with the following thermal conditions: 142 
42°C for 35 min, 55°C for 25 min, 70°C for 15 min and 5°C for 15 min. All primers used 143 
in this work were synthesized by Eurofins MWG Operon, Ebersberg, Germany. 144 
 145 
Primary PCR (pPCR) was done using Advantage cDNA Polymerase according to the 146 
supplier’s protocol (Clontech Laboratories, Inc.Mountain, View, USA) with some 147 
modifications. Reverse and forward primers RT2 and D1818 (5’-148 
AGAAGAAATGATGACAGCATGTCAGGGAGT-3`) were used. The pPCR mix 149 
contained 5 µL 10x Advantage buffer (Clontech), 10 µL dNTP mix (2 mM), 2 µL reverse 150 
primer RT2 (10 µM), 2 µL forward primer D1818 (10 µM), 1 µL Advantage Polymerase 151 
(5U/µL) and 4 µL of cDNA. Reaction profile was 94°C for 2 min, 94°C for 20 sec, 47°C 152 
for 20 sec, 68°C for 2 min, 30 cycles followed by a final elongation step at 68°C for 5 153 
min.  154 
 155 
A fragment of 645 bp spanning positions 23 – 236 in the reverse transcriptase gene was 156 
then amplified by nested PCR (nPCR). The nPCR mix contained 5 µL 10x Pfu buffer 157 
(Promega Corporation, Woods Hollow Road, Madison, WI USA), 10 µL dNTP mix (2 158 
mM), 2 µL forward primer JG103 5`-AACAATGGCCATTGACAGAA[I-Q]-3` (10 µM), 2 159 
µL reverse primer JG202 5`-TCAGGATGGAGTTCATAICCCA-3` (10 µM), 0.7 µL 160 
FIREPol Polymerase (3U/µL), 0.1 µL Pfu Polymerase (3U/µL) and 2 µL pPCR product. 161 
Thermocyling conditions were: 94°C for 2 min, followed by 30 cycles of 94°C for 15 sec, 162 
47°C for 15 sec, 72 °C for 2 min and a final elongation step at 72°C for 5 min.  163 
 164 
Nucleotide Sequencing  165 
Direct Sanger sequencing of PCR products from field samples and cloned HIV-1 166 
genome fragments was performed as previously described (Masimba et al., 2013 ). In 167 
brief, sequencing was performed either in our lab or by the commercial supplier 168 
Macrogen, South Korea. The in-house protocol used forward primers JG103 (5’-169 
AACAATggCCATTgACAgAA[I-Q]-3’) or PMF (5’-AACTCAAGACTTT TGGGAAGT-3’) or 170 
the reverse primers JG202 (5’-TCAggATggAgTTCATAICCCA-3’) or PMR (5’-171 
TTGTCATGCTACTCTGGAATA-3’). PMF and PMR are centrally located sequencing 172 
primers for the reverse transcriptase gene. Sequences were aligned using SeqScape 173 
Software Programme Version 2.7 (AB, Applied Biosystems, Foster City, CA). The 174 
sequence accession numbers are KC537065–KC537290.  175 
 176 
Design of Extension Primers, Tags and Anti-Tags 177 
Extension primers were designed for 25 prioritized DR-SNPs in the reverse 178 
transcriptase gene. Per SNP one or more extension primers were designed using a 179 
Clustalw1 alignment of 126 sequences from HIV-1 samples of patients from the 180 
KIULARCO cohort in Ifakara, Tanzania. Extension primers were designed in either the 181 
forward or reverse direction to maximize sequence conservation between the designed 182 
primer and the variety of template sequences. Single base extension (SBE) software (6) 183 
was used to design a set of 100 tags and anti-tags with the following parameters: length 184 
17-25 bp, melting temperature (Tm) 53-62°C, homodimer temperature 40°C. One 185 
individual tag was added to the 5` end of a single extension primer, whereby the SBE 186 
program was used to select the optimal tag/extension primer pairs by assessing Tm and 187 
potential for hairpin formation, homodimer and heterodimer formation. For spotting on 188 
microarrays 55 anti-tags, i.e. reverse complement of the tags selected for the extension 189 
primers, were synthesized via a C7 aminolinker for covalent coupling to the aldehyde 190 
glass slide. Oligonucleotides used as extension primers, anti-tags, as well as Cyanine 5 191 
(Cy5)- and Cyanine 3 (Cy3)-prelabeled oligonucleotides used as spotting controls and 192 
one additional Cy5-labeled hybrization control were all purchased from Eurofins. 193 
Labeled ddNTPs were purchased from Perkin Elmer, Schwerzenbach, Switzerland. 194 
 195 
Array design and production 196 
55 anti-tags plus 2 Cy3- and Cy5-prelabeled spotting controls were spotted at the 197 
Center of Integrative Genomics, University of Lausanne, Switzerland, on Arrayit 198 
aldehyde-coated slides with a 12 well mask (Supermask 12 Super Aldehyde Slides 199 
purchased from Anopoli Biomedical Systems, Eichgraben, Austria). Oligonucleotides 200 
were dissolved as a 10x stock (500µM) in 180 mM phosphate buffer pH 8.0 and spotted 201 
after dilution in spotting buffer (3xSSC buffer with 1.5 M betaine) at a concentration of 202 
50 μM (labeled spotting controls at a concentration of 0.5 μM). The array was printed in 203 
triplicate per masked well. After printing, slides were kept on a chamber at 50% relative 204 
humidity and baked the next day at 80°C for 90 min. 205 
 206 
Prior to hybridization slides were pre-incubated at 80°C for 90 min, followed by two 207 
washing steps for 2 min in 0.2% SDS and three times for 2 min in distilled water and 208 
was dried by centrifugation at 800 rpm for 5 min. Slides were reduced in 50mM 209 
triethanolamine titrated with boric acid to pH 8.0 at 50°C for 30 min, washed three times 210 
with 0.2% SDS for 1 min, then two times in distilled water for 1 min, and finally dried by 211 
centrifugation for 5 min at 800 rpm. Slides were then kept at room temperature in a dry, 212 
clean and dark place until used in hybridization experiments, usually on the same day or 213 
within one week. 214 
 215 
Primer Extension and hybridization 216 
Prior to the primer extension reaction, nested PCR products were subjected to a Shrimp 217 
Alkaline Phosphatase (SAP) digest (Amersham Biosciences, Freiburg, Germany) to 218 
eliminate all non-incorporated nucleotides. This reaction was carried out as previously 219 
described (Shafer et al., 2009). Primer extension with Cy3- and Cy5-labeled 220 
dideoxynucleotide triphosphates (Cy3-ddNTPs and Cy5-ddNTPs from Perkin Elmer) 221 
was carried out as described previously (Crameri et al., 2007). As the scanner 222 
supported only dual fluorescence measures, two extension reactions were performed 223 
with different permutations of Cy3- and Cy5- labeled ddNTPs. Table 1 shows the 224 
composition of both reaction mixes and indicates the required reaction mix for each 225 
extension primer. These two combinations of differentially labeled ddNTP were 226 
sufficient to differentiate all wild type from mutant alleles. Extension products from both 227 
reactions were combined before denaturation and hybridization performed as described 228 
previously (Crameri et al., 2007) with the modification that hybridization was performed 229 
at 550C for two hours. 230 
 231 
Washing  232 
After hybridization, slides were washed at room temperature (200C) in 3 consecutive 233 
buffers (temperature of the washing buffer was set at around 250C). One wash round 234 
consisted of 2X SSC + 0.2% SDS for 3 min., followed by 2X SSC for 2 min and finally 235 
2X SSC + 2% Ethanol for 1 min. The number of rounds depended on background 236 
fluorescence and fluorescence intensity of the spots. To adjust washing conditions to 237 
the background intensity, a slide was quickly dried with compressed air after each round 238 
and then pre-scanned. Further washing rounds were added if needed until the 239 
background fluorescence was satisfactorily removed without compromising signal 240 
intensity. Usually two to three rounds were sufficient.  241 
 242 
Image and Genotype Scoring 243 
After drying slides were scanned in a GenePix® microarray scanner 4100A (Axon 244 
Instruments, Genepix, USA) and images were stored as Tagged Image File Format 245 
(TIFF) file. Images were interpreted by running the GenePix software in combination 246 
with a file containing the array layout and a custom-made script. All spots with pre-247 
labeled tags or anti-tags gave strong signals at their defined locations and could thus be 248 
used to position the array. The data retrieved was stored in a GenePix Result (GPR) 249 
file, which was transferred to an in house generated receiver operating characteristic 250 
(ROC) Classifier program for SNP calling. This program evaluated and scored the 251 
triplicate hybridization signals for each SNP into wild type or mutant based on threshold 252 
values from a set of positive (triplicate spotting and hybridization controls and negative 253 
(unused anti-tags) controls present on each slide.  254 
 255 
Cloned HIV plasmids  256 
Four Cloned fragments of the HIV-1 genome were used for microarray validation. These 257 
fragments, derived from anonymous Swiss HIV-1 Cohort samples and cloned in puc18 258 
plasmid were made available from DBM, Haus Petersplatz, University of Basel (Fehr et 259 
al., 2011). After transformation the individual bacterial colonies were picked and plasmid 260 
DNA was extracted using QIAprep Miniprep Spin columns (Qiagen, Germany) 261 
according to the manufacturer’s instructions. Each cloned fragment represented a single 262 
HIV-1 reverse transcriptase gene variant suitable for assessing background 263 
hybridization and test validation. Plasmid inserts were of HIV-1 subtypes A, AE/A or C. 264 
The subtypes of cloned fragments were chosen to represent African HIV-1 subtypes. 265 
 266 
RESULTS 267 
 268 
Design of extension primers, tags and anti-tags 269 
For 25 SNPs in the reverse transcriptase gene, a total of 51 extension primers (1 to 8 270 
extension primers per SNP) were designed to compensate genetic diversity in the 271 
targeted sequence. Extension primers, tags and anti-tags are listed in Supplementary 272 
Table 1. Prior to the hybridization, all extension primers were tested by individual PCRs 273 
involving one of the extension primers plus either the forward or reverse primers 274 
normally used in our nPCR. As templates, four cloned reverse transcriptase gene 275 
fragments (subtypes A, CRF_02/AE and twice C) were used as well as 102 reverse 276 
transcription-PCR products from Tanzanian HIV-1 patients. All extension primers 277 
yielded DNA fragments of the expected size, indicating a sufficient degree of sequence 278 
conservation between these primers and the different templates tested 279 
(Supplementary Figure 1).  280 
 281 
Array design and spotting  282 
SBE software was used to select 55 oligonuclotide anti-tags and 2 spotting controls, the 283 
latter being produced with Cy3- or Cy5- fluorescent label at their 3’ end. One anti-tag 284 
was reserved for a hybridization control, for which the Cy5- pre-labeled tag was added 285 
to the extended primers prior to hybridization. Unused tags and printed buffer spots 286 
were used as negative controls. The array printed in Arrayit slides consisted of the 55 287 
anti-tags and controls in a 14 x 14 spot lay out (Figure 1), thus generating 3 data points 288 
for each position per sample. The separation of each slide by a hydrophobic mask into 289 
12 separate reaction areas or wells permitted parallel analysis of 12 patient samples per 290 
array. In contrast to the Cy3-control the Cy5-labeled spotting control was found to decay 291 
rapidly during storage of slides. We therefore used a hybridization control that also 292 
carried a Cy5- label for verifying hybridization success as well as for correct positioning 293 
of each array with the help of fixed and strong signals of control spots.  The results 294 
obtained from all pre-labeled controls confirmed a good reproducibility of the 295 
hybridization on microarray.  296 
 297 
Optimization of washing 298 
Despite systemic tag/anti-tag design, establishing of optimal wash conditions for 299 
hybridized slides was initially a challenge in generating optimal signal intensities for all 300 
spots of an array. The number of wash steps depended on the background 301 
fluorescence and the spot intensity on each particular slide and was therefore adapted 302 
after a pre-scan after each washing round. The majority of slides w washed three times, 303 
with each round consisting of 2X SSC + 0.2% SDS for 3 min, followed by 2X SSC for 2 304 
min and finally 2X SSC + 2% Ethanol for 1 min. Minor differences in slide pretreatment 305 
conditions and duration of storage could have contributed to these differences.  306 
 307 
Validation of microarray 308 
For validating the microarray’s accuracy in base calling we compared the SNP profile of 309 
a sample generated by microarray with the same SNPs derived from Sanger 310 
sequencing of the respective cloned HIV-1 genome fragment.  In contrast to PCR 311 
fragments from field samples, which may represent mixed populations of sequences, a 312 
cloned HIV-1 genome fragment harbors a single sequence and is therefore ideal for 313 
validating the specificity of hybridization on microarray and for determining individual 314 
anti-tags that give rise to hybridization background. Four cloned fragments representing 315 
sequences of subtypes C (2 clones), CRF_02/AE, and A2 were used for validation. The 316 
agreement between SNP profiles from microarray versus Sanger sequencing was 317 
perfect for 2 plasmids containing subtype C1 and A2 sequences (0720235-C1 and 318 
070510-A2). For another plasmid harbouring a subtype CRF_02/AE insert (6017225-319 
AE2) 88% (22/25) agreement was reached and 72% (18/25) for a subtype C1 insert 320 
(072073-C1). As all plasmid inserts were derived from patients in Switzerland, they 321 
likely represented variants with substantial sequence deviation from our extension 322 
primer sequences, which had been optimized for Tanzanian subtypes. Overall the 323 
concordance between both typing methods was 90%, the data for each SNP tested is 324 
shown in supplementary Table 2. 325 
 326 
Next, our HIV-1 SNP array was validated by genotyping 102 field samples from HIV-1 327 
patients from Ifakara, Tanzania. The agreement between microarray and Sanger 328 
sequencing was 92.7% (2363/2550) (supplementary Table 2). Extension primers of 5 329 
SNPs had a concordance of 100%. 14 SNPs had a concordance of >90% and only one 330 
SNP had a concordance of <70% compared to the respective SNPs determined by 331 
Sanger sequencing. The SNPs with 100% agreement were: M41L1, L74V, V75I, 332 
T215FY and K219E. The SNPs with between 90% - 99% agreement were: M41L, 333 
D67E, K70R, T215FY1, T215FY2 and L74I (99%), K219Q (98%), L100I, Y181C and 334 
M184V (96.1%), M184I (95.1%), G190A and K103N (93.1%). The SNPs with <90% 335 
agreement were: D67N (87.3%), Y188L1 (86.3%), K219N (78.4%), K65R (76%), Y188l2 336 
(71.6%) and L210W (62.7%). The L210W SNP principally performed poorly compared 337 
to all other SNPs. The sequence alignment of all 102 Tanzanian samples tested 338 
sequences revealed a number of mismatches with the designed extension primer in 339 
samples, which failed to produce a signal. Thus, the extension primer for SNP L210W 340 
was located in a region of considerable natural polymorphism (supplementary Table 341 
3), and we failed to design a reliable primer, which would harbour less than three 342 
mismatches with any of the sequences. To address the polymorphism around SNP 343 
L210W, 8 related extension primers reflecting the possible sequences were designed 344 
for this SNP alone, but still only 62.7% of samples yielded a signal with this complex 345 
array. Primer mismatches are likely to be the main reason for missing data for false 346 
positive signals at this site. Another SNP, Y181C, initially also underperformed, but we 347 
re-designed a set of 5 representative extension primers for this SNP which yielded 348 
correct signals for 96% of samples.  349 
 350 
DISCUSSION 351 
The reliable microarray-based SNP typing approach, originally developed and in use for 352 
genotyping drug resistance markers of the malaria parasite Plasmodium falciparum 353 
(Crameri et al., 2007) was now applied for genotyping DR-SNPs in the reverse 354 
transcriptase gene of HIV-1. The high mutation rate and genetic diversity were the 355 
toughest hurdles for a solely hybridization-based test. Our approach tried to overcome 356 
this challenge by (i) performing allelic discrimination by applying the mini-sequencing 357 
principle, and (ii) adapting the primers to the regionally prevailing viral strains. Our 358 
microarray hybridization was limited to perfectly base-paired tags and anti-tags, and we 359 
opted for adequate primer binding to diverse field isolates. Limitations in homology 360 
between sample and primers are the major challenges in developing a genotyping chip 361 
for HIV.  362 
The overall aim of this development was to provide a cost-effective alternative to 363 
classical sequencing for resource poor setting, by typing only the minimal essential 364 
SNPs for the regionally available therapies.  365 
 366 
On HIV-1 samples from Tanzania and with primers for 25 SNPs we were able to 367 
correctly identify 92% of all data points. As perfectly optimized sequences performed 368 
very reliably and with high sensitivity, we attributed suboptimal performance and 369 
missing data for certain mutations to mismatches of sample to primer. When we 370 
investigated the SNPs that had failed to produce signal we found that >3 mismatches 371 
within an extension primer was detrimental to hybridization and detection, while <3 372 
primer mismatches located in the central position of the primer did not greatly affect 373 
PCR efficiency. As was known, also primer mismatches located within 4 nucleotides 374 
from the 3` terminus compromised PCR efficiency.  375 
When disregarded (preliminary) extension primers, which in none of the experiments 376 
yielded a signal (i.e. 187/2550 SNPs), the concordance of microarray SNP profiles with 377 
Sanger sequencing reached 98%. To limit mismatching for distant HIV isolates we 378 
designed additional primers specific for some resistance positions. Since there was 379 
space for additional primers (due to our design for a limited number of reverse 380 
transcriptase mutations) we chose to use up to 5 primers for difficult positions or to 381 
incorporate wobbles at polymorphic positions: E.g. the design of five specific primers for 382 
Y181C yielded 96.1% success, and with four primers for K103N we obtained a signal in 383 
93.1%. Only for SNP K210W despite the design of eight different extension primers we 384 
failed to reliably produce typing results for this SNP which resides within a hypervariable 385 
region of the gene.  386 
 387 
A major task in the further development of this microarray will be to reduce the number 388 
of missing data, achievable by designing additional extension primers or by optimizing 389 
primer-annealing conditions, i.e. annealing temperature, duration, or salt concentration 390 
in the multiplex extension reaction. The advantage of a microarray with spotted anti-tags 391 
is that it is very flexible and allows addition of more or new tagged extension primers to 392 
the reaction for new mutations or new drug-resistance patterns.  393 
  394 
This SNP-Microarray was developed primarily for population studies, e.g. for 395 
determining the prevalence of transmitted DR-SNPs, or for identifying reasons for 396 
treatment failure. For such questions, the deliberately limited set of informative SNPs 397 
genotyped by this method is adequate. For other research questions or for individual 398 
diagnosis Sanger sequencing is more advantageous, as complete sequence 399 
information is gained.  400 
 401 
CONCLUSION 402 
Genotyping by microarray yielded a good agreement with Sanger sequencing in 102 403 
field samples from Tanzania and resulted in correct base calling for 92% of SNPs. To 404 
generate complete DR haplotypes suitable for diagnostic purposes, further optimization 405 
will be required. Given the simplicity of its use, and a fairly short processing time to 406 
results, this hybridization-based microarray has demonstrated potential for monitoring 407 
resistance mutations in population-wide studies. The SNP-specific primers designed for 408 
this study may be equally useful for developing other hybridization-based genotyping 409 
tools, such as SNP typing on a bioplex platform or probe-based PCR applications.  410 
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Figure legends 418 
 419 
Figure 1.   HIV-1 SNP typing microarray. (A) Design and layout of microarray. 420 
Triplicates are depicted in different colours. T1, TC59, TC60, T61 and blnk denote Cy5- 421 
spotting control-2, Cy5- spotting control-1, Cy3- spotting control, Cy3- pre-labeled 422 
hybridization control and printed buffer spots (blank), respectively.  Some of the anti-423 
tags were not in use in this experiment (T35, T36, T37, T48 and T52) and therefore 424 
utilized as negative control for calculating the cut-off. (B) Image of a HIV-1 SNP typing 425 
microarray after hybridization with a Tanzanian field sample. Each array consists of 426 
14x14 spots. Cy5- spotting control (degenerated, indicated by green circles); Cy3- 427 
spotting control (red circles); Cy5-prelabeled hybridization control (blue circle); example 428 
of missing data (white circle).  429 
 430 
Supplementary Figure 1.  Validation of extension primers by PCR on cloned reverse 431 
transcriptase fragments and viral cDNA from Tanzania. Expected fragment sizes range 432 
from 56- 645 bp. 433 
 434 
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Table 1. Composition of Extension Primer and ddNTP reaction mixes 468 
 469 
Extension Primer Mix 1 Extension Primer Mix 2 
T-2-A-M41L ATTTTTGAAATTTTTCCTTCCTTTTCCA  T-1-A_K103N CCCACATCCAGTACTGTCACTGATTT  
T-3-S_K65R TATAACACTCCAGTATTTGCCATAAAAA T-5-A_D67E AAATCTACTAATTTTCTCCACTTAGTACT  
T-4-A_D67N ATCTACTAATTTTCTCCACTTAGTACTGT T-8-A_L74V TCTTTTATTGAGTTCTCTGAAATCTACTA 
T-6-A_K70R TCCCTGAAATCTACTAATTTTCTCCACT  T-10-A_L100I AGTACTGTCACTGATTTTTTCTTTTTTA 
T-7-S_K70R ATTTGCCATAAAAAAGAAGGACAGTACTA T-13-S_Y188L2 ATCTATCAATACATGGATGACTTGT  
T-9-A_V75I AGTTCTTTTATTGAGTTCTCTGAAATCTA  T-15-S_G190A TCTATCAATACATGGATGACTTGTATGTA 
T-11-S_Y181C 
TAGAGCACAAAATCCAGAAATAGTTATCT T-16-S_L210W AGAGGAGTTAAGAGCACATCTAT  
T-12-A_Y188L1 TGCCCTATTTCTAAGTCAGATCCTAC T-18-S_T215FY1 TAAGAGGACATCTATTGAGGTGGGGATTT  
T-14-A-G190A 
CTCTATGCTGCCCTATTTCTAAGTCAGAT  T-19-A-K219Q ATGGAGGTTCTTTCTGATGTTTYT 
T-17-A_T215FY1 TTCTGATGTTTCTTGTCTGGTGTG T-20-S_M41L AGTGACAGTACTGGATGTGGGGG  
T-23-A_T215FY2 
TTCTTTCTGATGTTTCTTGTCTGGTGTG T-21-S_T215FY AGAGGACATCTATTGAGGTGGGGATTTA 
T-24-A_L74I CTTTTATTGAGTTCTCTGAAATCTACTA T-22-A_T215FY TTCTGATGTTTTTTGTCTGGTGTG  
T-28-S_184I AACCCAGAAATAGTTATCTATCAATATAT T-27-A_K219N GAAATGGAGGTTCTTTCTGATGTTT 
T-29-A_184V 
TAAATCAGATCCTACATACAAGTCATCCA  T-31-S_L74V AAGGACAGTACTAAGTGGAGAAAA  
T-30-S_L74I AAGAAGGACAGTACTAAGTGGAGAAAA T-33-S_L100I GGATACCACACCCAGCAGGG  
T-32-S_L75I AAGGACAGTACTAAGTGGAGAAAATTA T-33.2-S-L100I GGATACCACACCCAGCGGGG 
160L74I1.1 ATTGAGTTCCCTGAAATCTACTA T-34-S-K103N ACACCCAGCAGGGTTGAAAAAGAA  
78M184V1.1 AGATCCTACATACAAATCATCCA 17M41L1.1 TTTGTAATTTTTCCTTCCTTTTCCA  
144K219E1.1 TGGGGATTTACCACACCAGAC 02K103N1.1 ACATCCAGTACTGTCACTGATTT  
T-02.1-A-Y181C ACATACAAGTCATCCATATATTGA 130L210W1.1 TCTGGTGTGGTAAATCCCCATTTI  
T-38-A-Y181C ACATACAAGTCATCCATGTATTGA T-39-S-L210W  AGAGGAGTTAAGAGCACAYTTAT 
T-40-A-Y181C ACATACAAGTCATCCACATATTGA T-38-S_L210W AGAGGAGTTAAGAGCACATCTST 
T-45.1-A-Y181C ACATACAAGTCATCCACATATTGA T-41-A-L210W TCTCGTCTGGAGTGAAAAATCCCCATTTT 
T-45-A-Y181C CATACAAGTCATCCACATATTGG T-42-S-L210W AGAGGAGTTAAGAGCWCACCTAT  
T-50-S-L100I GGATACCACACCCAGCAGGI T-43-S-L210W  AGAGGAGTTAAGAGCWCATCTAT  
 T-44-A-L210W TCTTGTCTGGTGTGGTAAATCCCCATTTC 
 T-46-S-K219Q TGGGGATTTACCACACCAGAI 
 T-47-A-L210W TTTTGTCTGGTGTGGTAAACCCCCACTTC 
 T-49-A-L210W TCTTGTCTGGTGTGGTAAATCCCCACCTT 
 T-51-S- K219Q TGGGGATTTACCACACCAGAC 
 
Dideoxy-dNTP Mix 1 Dideoxy-dNTP Mix 2 
ddATP-CY3 ddUTP-CY3 
ddCTP-CY3 ddCTP-CY3 
ddGTP-CY5 ddATP-CY5 
ddUTP-CY5 ddGTP-CY5 
 470 
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 472 
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 474 
 475 
 476 
 477 
478 
 479 
Fig. 2 Fig. 3
 480 
 481 
Figure 1.   A     B 482 
 483 
484 
Supplementary Table 1. List of extension primers, tags and anti-tags and spotting and 485 
hybridization controls. 486 
 487 
Extension Primer (5´→3´) Tag (5´→3´) Anti-Tag (5´→3´) 
T-1-A_K103N 
CCCACATCCAGTACTGTCACTGATTT T-1 GGTTCCCGATTTATCGATCCC 
AT-1 
GGGATCGATAAATCGGGAACC 
T-2-A-M41L 
ATTTTTGAAATTTTTCCTTCCTTTTCCA 
T-2 
CATGTGGTACAATGGAACAGCTA
CT 
AT-2 
AGTAGCTGTTCCATTGTACCA
CATG 
T-3-S_K65R 
TATAACACTCCAGTATTTGCCATAAAAA T-3 TCAGGGAACTTCGATGCTGC 
AT-3 
GCAGCATCGAAGTTCCCTGA 
T-4-A_D67N 
ATCTACTAATTTTCTCCACTTAGTACTG
T T-4 GACTGACCCGCTTGAGTTAGT 
AT-4 
ACTAACTCAAGCGGGTCAGT
C 
T-5-A_D67E 
AAATCTACTAATTTTCTCCACTTAGTAC
T 
T-5 
GTTCAATCAGAAAACACCTGCGG 
AT-5 
CCGCAGGTGTTTTCTGATTG
AAC 
T-6-A_K70R 
TCCCTGAAATCTACTAATTTTCTCCACT T-6 CTGCAAGCAGGTTGTGCTCT 
AT-6 
AGAGCACAACCTGCTTGCAG 
T-7-S_K70R 
ATTTGCCATAAAAAAGAAGGACAGTAC
TA T-7 GGCGGTTCATGGAATTCCC 
AT-7 
GGGAATTCCATGAACCGCC 
T-8-A_L74V 
TCTTTTATTGAGTTCTCTGAAATCTACT
A 
T-8 
GTCCTACGTCGAGTAGAGAAAGT
C 
AT-8 
GACTTTCTCTACTCGACGTAG
GAC 
T-9-A_V75I 
AGTTCTTTTATTGAGTTCTCTGAAATCT
A 
T-9 
CATTTGCGTTTCTCTGGGTAATGC 
AT-9 
GCATTACCCAGAGAAACGCA
AATG 
T-10-A_L100I 
AGTACTGTCACTGATTTTTTCTTTTTTR T-10 CCTGTCGGGAGCAGTACA 
AT-10 
TGTACTGCTCCCGACAGG 
T-11-S_Y181C 
TAGAGCACAAAATCCAGAAATAGTTAT
CT 
T-11 
ATCTACTACCACCTCCAACGG 
AT-11 
CCGTTGGAGGTGGTAGTAGA
T 
T-12-A_Y188L1 
TGCCCTATTTCTAAGTCAGATCCTAC 
T-12 
GGGCGGACTACATCGAAATTACC 
AT-12 
GGTAATTTCGATGTAGTCCG
CCC 
T-13-S_Y188L2 
ATCTATCAATACATGGATGACTTGT  
T-13 
CCGAAACAACGCAGAACTCAC 
AT-13 
GTGAGTTCTGCGTTGTTTCG
G 
T-14-A-G190A 
CTCTATGCTGCCCTATTTCTAAGTCAG
AT T-14 CTCTCCACAGTGCAGCGA 
AT-14 
TCGCTGCACTGTGGAGAG 
T-15-S_G190A 
TCTATCAATACATGGATGACTTGTATGT
A T-15 TGGCCTTGTGAATCCACCC 
AT-15 
GGGTGGATTCACAAGGCCA 
T-16-S_L210W 
AGAGGAGTTAAGAGCACATCTAT1 
 
T-16 
CGAAAAACCACGCCGTATTTCA 
AT-16 
TGAAATACGGCGTGGTTTTTC
G 
T-17-A_T215FY1 
TTCTGATGTTTCTTGTCTGGTGTG 
T-17 
TCACTTACGACCGTTTTGTCTACA 
AT-17 
TGTAGACAAAACGGTCGTAA
GTGA 
T-18-S_T215FY1 
TAAGAGGACATCTATTGAGGTGGGGAY
TT  T-18 GAGAGGCATGCGTTTCACG 
AT-18 
CGTGAAACGCATGCCTCTC 
T-19-A-K219Q 
ATGGAGGTTCTTTCTGATGTTTYT 
T-19 
GACCGGCAATTCGTTATCCAC 
AT-19 
GTGGATAACGAATTGCCGGT
C 
T-20-S_M41L 
AGTGACAGTACTGGATGTGGGGG 
T-20 
GTCAAATTCGACAGCTGGAAGG 
AT-20 
CCTTCCAGCTGTCGAATTTGA
C 
T-21-S_T215FY 
AGAGGACATCTATTGAGGTGGGGATTT
A 
T-21 
GAAGCCGTCTCTGTTGTTTTCC 
AT-21 
GGAAAACAACAGAGACGGCT
TC 
T-22-A_T215FY T-22 CAGAGATCCATTGGCGCGT AT-22 
TTCTGATGTTTTTTGTCTGGTGTI ACGCGCCAATGGATCTCTG 
T-23-A_T215FY2 
TTCTTTCTGATGTTTCTTGTCTGGTGTY 
T-23 
CGCATAATGACCCAACTTCGAG 
AT-23 
CTCGAAGTTGGGTCATTATG
CG 
T-24-A_L74I 
CTTTTATTGAGTTCTCTGAAATCTACTA T-24 GCTGCCGGCTATTTTTGGAG 
AT-24 
CTCCAAAAATAGCCGGCAGC 
T-27-A_K219N 
GAAATGGAGGTTCTTTCTGATGTTT 
T-27 
CCCCCGAGAAGGTTTATGTTTAAC 
AT-27 
GTTAAACATAAACCTTCTCGG
GGG 
T-28-S_184I 
AACCCAGAAATAGTTATCTATCAATATA
T T-28 AGCCTCGGGTCTACATCGT 
AT-28 
ACGATGTAGACCCGAGGCT 
T-29-A_184V 
TAAATCAGATCCTACATACAAGTCATC
CA T-29 CAGCAGTCCGATGCCTGG 
AT-29 
CCAGGCATCGGACTGCTG 
T-30-S_L74I 
AAGAAGGACAGTACTAAGTGGAGAAAA 
T-30 
CGCCTAGACCTTTTAGCTAGCC 
AT-30 
GGCTAGCTAAAAGGTCTAGG
CG 
T-31-S_L74V 
AAGGACAGTACTAAGTGGAGAAAA T-31 GGAGCTTTTGCTGTTCGGTC 
AT-31 
GACCGAACAGCAAAAGCTCC 
T-32-S_L75I 
AAGGACAGTACTAAGTGGAGAAAATTA 
T-32 
CGGGGTATGACATACTATTGACCA 
AT-32 
TGGTCAATAGTATGTCATACC
CCG 
T-33-S_L100I 
GGATACCACACCCAGCAGGG  T-33 GTTGGCGGGTTATTACAGGG 
AT-33 
CCCTGTAATAACCCGCCAAC 
T-34-S-K103N 
ACACCCAGCAGGGTTGAAAAAGAA  T-34 TGCGATTGTATACCCGCTCC 
AT-34 
GGAGCGGGTATACAATCGCA 
  
 
AT-35 
GCGTAAATCATACGCCTGGG
TC2 
  
 
AT-36 
ACGCGTTACGTTAGAGATAA
GGCTA2 
  
 
AT-37 
GCCTCCACCCTTCTCAAGAA
TA2 
T-38-S_L210W 
AGAGGAGTTAAGAGCACATCTsT1 
 T-38 TTTCCGGATTCACCCGTACC 
AT-38 
GGTACGGGTGAATCCGGAAA 
T-39-S-Y181C 
TAGAGCACAAAATCCAGAAATAGTTAT
wT T-39 GATCGGACGACGCTTGGG 
AT-39 
CCCAAGCGTCGTCCGATC 
T-40-A-Y181C 
ACATACAAGTCATCCACATATTGA T-40 TAGAGGAGGCGGGAGTTTTT 
AT-40 
AAAAACTCCCGCCTCCTCTA 
T-41-A-L210W 
TCTCGTCTGGAGTGAAAAATCCCCATT
TT1 
 
T-41 
AGCCAATGAATGACAATTCGTGCA 
AT-41 
TGCACGAATTGTCATTCATTG
GCT 
 T-42 GCACCACAGTCCGGTATTGC 
AT-42 
GCAATACCGGACTGTGGTGC 
T-43-A-K103N 
CCCACATCCAATACTGTTACTGACTT T-43 TTTCACACACGGCCACTTTTC 
AT-43 
GAAAAGTGGCCGTGTGTGAA
A 
T-44-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCATT
TC1 
 
T-44 
TGTTTGAACTAGTGGCGTCACG 
AT-44 
CGTGACGCCACTAGTTCAAA
CA 
T-45-A-Y181C 
CATACAAGTCATCCACATATTGG T-45 GGTGATAGGCAACGAGGTCT 
AT-45 
AGACCTCGTTGCCTATCACC 
T-46-S-K219Q 
TGGGGATTTACCACACCAGAI 
T-46 
GGGGATCCTAGACTTTGATGCT 
AT-46 
AGCATCAAAGTCTAGGATCC
CC 
T-47-A-L210W 
TTTTGTCTGGTGTGGTAAACCCCCACT
TC1 
 
T-47 
CTTAGTCCTCTGACTGTCTCTGTC 
AT-47 
GACAGAGACAGTCAGAGGAC
TAAG 
   
AT-48 
GACACACTTGTTGGACGCAA
G2 
T-49-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCACC
TT1 
 
T-49 
GTGTTTGTCTACTTCGTGTGTGC 
AT-49 
GCACACACGAAGTAGACAAA
CAC 
T-50-S-L100I 
GGATACCACACCCAGCAGGI 
T-50 
ATGGAACCTATAATCTAGGATGGC
G 
AT-50 
CGCCATCCTAGATTATAGGTT
CCAT 
T-51-A-L210W  
TTTTGTCTGGGGTAGTCAATCCCCAGC
TC1 
 
T-51 
TCGTATAAGTCACGTTCTCCTTGG 
AT-51 
CCAAGGAGAACGTGACTTAT
ACGA 
  
 
AT-52 
CATTACTCCCTCCCGTCATGT
2 
17M41L1.1 
TTTGTAATTTTTCCTTCCTTTTCCA 
17.1 
CAACATCATCACGCAGAGCATCAT
T 
17.1 
AATGATGCTCTGCGTGATGA
TGTTG 
160L74I1.1 
ATTGAGTTCCCTGAAATCTACTA 
160.1 
CCACGTACTGTCCGGAATACACG
AC 
160.1 
GTCGTGTATTCCGGACAGTA
CGTGG 
02K103N1.1 
ACATCCAGTACTGTCACTGATTT 
02.1 
TGCCCCGTTGCCCCGTTGCCCCG
T 
02.1 
ACGGGGCAACGGGGCAACG
GGGCA 
75Y181C1.1 
CATACAAGTCATCCATATATTGA 
75.1 
TAACACAAGAGCAGCTTGAGGAC
G 
75.1 
CGTCCTCAAGCTGCTCTTGT
GTTA 
78M184V1.1 
AGATCCTACATACAAATCATCCA 
78.1 
ACAGCCTCGCAGATGACGAATCA
TT 
78.1 
AATGATTCGTCATCTGCGAG
GCTGT 
130L210W1.1 
TCTGGTGTGGTAAATCCCCATTTI1 
 
130.1.1 
TACCAACTGTATGCGCATGTGCAC
C 
130.1.1 
GGTGCACATGCGCATACAGT
TGGTA 
144K219E1.1 
TGGGGATTTACCACACCAGAC 
144.1.1 
TTCAGTGTATGACGACCAGAGCG
TT 
144.1.1 
AACGCTCTGGTCGTCATACA
CTGAA 
 
[Cy3]AGAAGATGCCTAGTATATG 
AT-61 
CATATACTAGGCATCTTCT 
 
 
[Cy5]ATGCAACCATCAAGT-
[AmC7~Q] 
 
 
[Cy3] 
GCTCAGCTGTATTAGAA- 
[AmC7~Q] 
 488 
1 Extension primers never giving a signal or with inconsistent performance 489 
2 Five additional anti-tags were designed and spotted to permit future use; these were utilized for 490 
quantification of background hybridization) 491 
 492 
493 
Supplementary Table 2. Comparison of microarray with direct sequencing using field 494 
samples and cloned DNA fragments. 495 
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Field Samples 
ET33 1 0 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22 
ET34 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
ET36 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 24 
ET37 1 0 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22 
ET39 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 22 
ET44 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
ET48 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 22 
ET50 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
ET53 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
ET56 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
ET59 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
5510266 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
5510423 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 22 
5510599 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 21 
5510305 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22 
5510377 1 0 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 20 
5510376 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
5510388 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23 
5511611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
5410055 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
5510060 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23 
5510184 1 0 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 0 1 1 1 21 
5510603 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
FTM 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22 
5510508 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 22 
5510026 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
5510817 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
5510236 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
5510718 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 22 
5510504 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22 
5510075 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
5510270 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 21 
5510135 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 23 
5514370 1 1 1 1 1 1 1 1 1 0 0 0 1 0 0 1 1 1 1 0 1 1 0 1 1 18 
HLM5 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
HLM 6 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 21 
HLM 7 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 0 0 1 1 1 21 
HLM 13 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 23 
HLM 17 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 23 
HLM 23 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 21 
HLM 25 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM29 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22 
ET 2 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 20 
HLM 32 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 35 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 36 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 38 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 69 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 71 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 73 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 74 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM76 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
HLM 77 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 78 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 79 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 80 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 83 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23 
HLM 86 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM 87 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 88 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
ET 7 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 0 1 1 19 
ET 7 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 1 0 1 1 1 1 1 0 1 1 19 
5514352 1 0 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 0 0 1 1 1 1 20 
5510255 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 0 1 1 1 22 
5511110 1 1 0 1 1 1 1 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 1 1 18 
5514391 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23 
HLM-89 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-91 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-92 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-93 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23 
HLM-172 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-173 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-175 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-176 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 24 
HLM-177 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-178 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-180 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 23 
HLM-181 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-182 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-185 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-258 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
HLM-259 1 1 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 22 
HLM-260 1 1 1 1 1 1 1 1 1 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 22 
HLM-261 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 0 1 1 22 
HLM-262 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 23 
HLM-263 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-264 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 23 
HLM-265 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 24 
HLM-267 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-182 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-271 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23 
HLM-267 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-182 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
HLM-271 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23 
05510783- 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24 
A 
5510075 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23 
ET 7 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 0 1 1 19 
HLM 88 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24 
HLM 80 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
07510783-
B 
1 1 1 1 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22 
% 
agreement 
99 76 87 99 99 100 100 96 96 86 72 93 93 63 99 99 98 100 99 78 95 96 93 100 100 92.7 
agreement 101 77 89 101 101 102 102 98 98 88 73 95 95 64 101 101 100 102 101 80 97 98 95 102 102 2363 
Cloned RT Fragments 
0720235-
C1 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
6017225-
AE2 
1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 0 1 0 1 1 1 1 22 
072073-C1 1 0 1 1 1 1 1 0 0 0 1 0 1 0 1 1 1 1 1 0 1 1 1 1 1 18 
070510-A2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
agreement 4 3 4 4 4 4 4 3 3 3 3 3 4 3 4 4 4 4 3 3 3 4 4 4 4 90 
 497 
498 
Supplementary Table 3. Location of L210W SNP in the Alignment of Ifakara RT sequences  499 
 500 
 501 
 502 
Circle represent the location of the L210 SNP, which is preceded by a region of high 503 
polymorphism 504 
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